Troy A. Ignelzi, Chief Financial Officer at Karuna Therapeutics, Inc. (KRTX), sold 2,860 shares at $174.88 ($501K) on 2023-08-22, disclosed to the SEC on 2023-08-24.
Scheduled sale ($501k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $173.64 | 80 | $14K | 2.8% |
| 2 | $174.88 | 855 | $150K | 29.9% |
| 3 | $174.88 | 855 | $150K | 29.9% |
| 4 | $175.59 | 505 | $89K | 17.7% |
| 5 | $175.59 | 505 | $89K | 17.7% |
| 6 | $176.60 | 60 |
| $11K |
| 2.1% |
| Total | $175.13 avg | 2,860 | $501K | 100% |
| Filing → |
| KRTX | SELL | 2023-02-23 | $1.1M | — | Filing → |
| KRTX | SELL | 2023-01-19 | $369K | — | Filing → |
| KRTX | SELL | 2022-11-17 | $3.7M | — | Filing → |